Drug Profile
Research programme: Cushing's syndrome therapy - Samaritan Pharmaceuticals
Alternative Names: SP-6300Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Georgetown University
- Developer Samaritan Pharmaceuticals
- Class
- Mechanism of Action HMG-CoA reductase inhibitors; RNA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cushing syndrome
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cushing's syndrome in USA
- 16 Jul 2009 An IND is active for SP 6300 for the treatment of Cushing's syndrome in US
- 16 Jul 2009 Samaritan is seeking a partnership to further develop SP 6300 (http://www.samaritanpharma.com/)